Email Address:
  
  Password:
  
  

EXHIBIT 10.44

 

AMENDMENT #1 TO THE
CLINICAL TRIAL AGREEMENT BETWEEN
VION PHARMACEUTICALS, INC. AND THE
DIVISION OF CANCER TREATMENT AND DIAGNOSIS, NCI
DATED MARCH 2, 2006

 

The purpose of this amendment (“Amendment”), effective as of the last date signed below (“Effective Date”), is to change certain terms of the above referenced Clinical Trials Agreement (CTA) (“Agreement”). These changes are reflected below and except for these changes, all other provisions remain in full force and effect. Two (2) originals of this amendment are provided for execution; one is to remain with the National Cancer Institute, and the second is to remain with Vion Pharmaceuticals.

 

1.  

Expiration Date

 

The CTA shall be amended to extend the term for conducting clinical studies with this Agent for a period of two (2) years. The date of expiration of this CTA is now January 9, 2008.

 

2.  

Article 1. Definitions

 

“CTIS” means Capital Technology Information Service.

 

3.  

Article 6. Drug Information and Supply

 

Article 6 is hereby amended as follows:

 

The contact person for DCTD will be Mr. Charles Hall, Chief,


This is only a partial view of this document. We have millions of legal documents and clauses drafted by top law firms. learn more search for free browse for free learn more